Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Severe acute respiratory syndrome (SARS) coronavirus (COV)-2 causes flu-like symptoms, including fever, cough, fatigue, and loss of sense of smell. Although many complications of this unprecedented virus have been specified, there is still a lack of information on neurologic post-recovery complications. Studies suggest that this rapidly spreading virus can invade the nervous system and cause neurological problems even after recovery. 1 The most common neurological complications include headache, dizziness, myalgia, anosmia, gustatory, and olfactory dysfunctions. 2 Severe disorders such as encephalopathy, encephalitis, necrotizing hemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis, and Guillain-Barre syndrome have also been reported after coronavirus disease (COVID)-19 infection. 3 There are just six case reports on post-COVID-19 chorea. As far as we know, the two patient cases noted below are the first to be reported with more than a 2-week interval between post-COVID-19 encephalitis and initiation of chorea. [4][5][6][7][8][9][10][11] A 67-year-old woman was referred to the movement disorder clinic because of acute onset of generalized choreiform movements. She stated an earlier admission because of coronavirus symptoms including nausea, loss of appetite, and high blood pressure 3 months prior. Moreover, she tested positive for coronavirus reverse-transcription polymerase chain reaction (RT-PCR) by nasopharyngeal swab. Additionally, 2 weeks after the beginning of her COVID-19 infection, she developed confusion, illusion, aphasia, imbalance, and delirium. Consequently, she was diagnosed with post-COVID-encephalitis and received a tocilizumab injection. She was vaccinateded for COVID-19 (AstraZeneca) 4 months previously. Her family history and previous history of any abnormal movements in any part of her body were negative.She had normal neurological and systemic examinations. However, she was suffering from choreiform movements in her face and all four limbs, with right arm dominancy (Video 1). Brain magnetic resonance imaging (MRI) showed bilateral hyperintensity on fluid-attenuated inversion recovery and T2 imaging on basal ganglia (Fig. 1). She was treated with tetrabenazine (12.5 mg twice daily). After a few days, her symptoms recovered rapidly, and she was discharged.Another 62-year-old otherwise healthy female presented to the movement disorder clinic because she experienced sudden onset abnormal movements in her truncal and limbs. She had been admitted 15 days previously because of her COVID-19 infection and treated with a remdesivir injection. Her past medical history, drug history, and family history were unremarkable. She had no pathological findings in examinations and brain MRI. Nonetheless, she had choreiform movements on her extremities, especially on the right side (Video 2). She was treated with tetrabenazine and chorea dramatically mended.Video 1. Shows the patient with choreiform movements in face and all four limbs, more prominently in the right upper extremity.
Severe acute respiratory syndrome (SARS) coronavirus (COV)-2 causes flu-like symptoms, including fever, cough, fatigue, and loss of sense of smell. Although many complications of this unprecedented virus have been specified, there is still a lack of information on neurologic post-recovery complications. Studies suggest that this rapidly spreading virus can invade the nervous system and cause neurological problems even after recovery. 1 The most common neurological complications include headache, dizziness, myalgia, anosmia, gustatory, and olfactory dysfunctions. 2 Severe disorders such as encephalopathy, encephalitis, necrotizing hemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis, and Guillain-Barre syndrome have also been reported after coronavirus disease (COVID)-19 infection. 3 There are just six case reports on post-COVID-19 chorea. As far as we know, the two patient cases noted below are the first to be reported with more than a 2-week interval between post-COVID-19 encephalitis and initiation of chorea. [4][5][6][7][8][9][10][11] A 67-year-old woman was referred to the movement disorder clinic because of acute onset of generalized choreiform movements. She stated an earlier admission because of coronavirus symptoms including nausea, loss of appetite, and high blood pressure 3 months prior. Moreover, she tested positive for coronavirus reverse-transcription polymerase chain reaction (RT-PCR) by nasopharyngeal swab. Additionally, 2 weeks after the beginning of her COVID-19 infection, she developed confusion, illusion, aphasia, imbalance, and delirium. Consequently, she was diagnosed with post-COVID-encephalitis and received a tocilizumab injection. She was vaccinateded for COVID-19 (AstraZeneca) 4 months previously. Her family history and previous history of any abnormal movements in any part of her body were negative.She had normal neurological and systemic examinations. However, she was suffering from choreiform movements in her face and all four limbs, with right arm dominancy (Video 1). Brain magnetic resonance imaging (MRI) showed bilateral hyperintensity on fluid-attenuated inversion recovery and T2 imaging on basal ganglia (Fig. 1). She was treated with tetrabenazine (12.5 mg twice daily). After a few days, her symptoms recovered rapidly, and she was discharged.Another 62-year-old otherwise healthy female presented to the movement disorder clinic because she experienced sudden onset abnormal movements in her truncal and limbs. She had been admitted 15 days previously because of her COVID-19 infection and treated with a remdesivir injection. Her past medical history, drug history, and family history were unremarkable. She had no pathological findings in examinations and brain MRI. Nonetheless, she had choreiform movements on her extremities, especially on the right side (Video 2). She was treated with tetrabenazine and chorea dramatically mended.Video 1. Shows the patient with choreiform movements in face and all four limbs, more prominently in the right upper extremity.
Background: COVID-19 infection is associated with neurological manifestations, including various types of movement disorders (MD). A thorough review of individual patients with COVID-19-induced MD would help in better understanding the clinical profile and outcome of these patients and in prognostication. Objective: We conducted an individual patient-systematic review to study the clinical and imaging profile and outcomes of patients with COVID-19-associated MD. Methods: A systematic literature search of PubMed, EMBASE, and Cochrane databases was conducted by two independent reviewers. Individual patient data COVID from case reports and case series on COVID-19-associated MD, published between December 2019 and December 2022, were extracted and analyzed. Results: Data of 133 patients with COVID-19-associated MD from 82 studies were analyzed. Mean age was 55 ± 18 years and 77% were males. A mixed movement disorder was most commonly seen (41%); myoclonus-ataxia was the most frequent (44.4%). Myoclonus significantly correlated with age (odds ratio (OR) 1.02 P = 0.03, CI 1-1.04). Tremor had the longest latency to develop after SARS-CoV-2 infection [median (IQR) 21 (10-40) days, P = 0.009, CI 1.01-1.05]. At short-term follow-up, myoclonus improved (OR 14.35, P value = 0.01, CI 1.71-120.65), whereas parkinsonism (OR 0.09, P value = 0.002, CI 0.19-0.41) and tremor (OR 0.16, P value = 0.016, CI 0.04-0.71) persisted. Conclusion: Myoclonus-ataxia was the most common movement disorder after COVID-19 infection. Myoclonus was seen in older individuals and usually improved. Tremor and parkinsonism developed after a long latency and did not improve in the short-term.
Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily involves the cardiovascular and respiratory systems, neurological manifestations, including movement disorders such as myoclonus and cerebellar ataxia, have also been reported. However, the occurrence of post-SARS-CoV-2 chorea is rare. Herein, we describe a 91-year-old female with a past medical history of hypothyroidism who developed chorea after two weeks of contracting a mild coronavirus disease (COVID-19).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.